The combined application of CSF Aβ42/Aβ40 and other CSF biomarkers, e.g., T-tau or P-tau, gave a better prediction of AD (Baldeiras et al., 2018) and the conversion from MCI to AD (Baldeiras et al., 2018; Mahaman et al., 2022). This evidence concerns the gene MAPT and Alzheimer disease.